312 related articles for article (PubMed ID: 21826083)
1. Cancer immunology--analysis of host and tumor factors for personalized medicine.
Ogino S; Galon J; Fuchs CS; Dranoff G
Nat Rev Clin Oncol; 2011 Aug; 8(12):711-9. PubMed ID: 21826083
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.
Ogino S; Chan AT; Fuchs CS; Giovannucci E
Gut; 2011 Mar; 60(3):397-411. PubMed ID: 21036793
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
5. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor
Hamada T; Soong TR; Masugi Y; Kosumi K; Nowak JA; da Silva A; Mu XJ; Twombly TS; Koh H; Yang J; Song M; Liu L; Gu M; Shi Y; Nosho K; Morikawa T; Inamura K; Shukla SA; Wu CJ; Garraway LA; Zhang X; Wu K; Meyerhardt JA; Chan AT; Glickman JN; Rodig SJ; Freeman GJ; Fuchs CS; Nishihara R; Giannakis M; Ogino S
Oncoimmunology; 2018; 7(7):e1442999. PubMed ID: 29900052
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
[TBL] [Abstract][Full Text] [Related]
7. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer.
Nosho K; Sukawa Y; Adachi Y; Ito M; Mitsuhashi K; Kurihara H; Kanno S; Yamamoto I; Ishigami K; Igarashi H; Maruyama R; Imai K; Yamamoto H; Shinomura Y
World J Gastroenterol; 2016 Jan; 22(2):557-66. PubMed ID: 26811607
[TBL] [Abstract][Full Text] [Related]
8. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma.
Mima K; Sukawa Y; Nishihara R; Qian ZR; Yamauchi M; Inamura K; Kim SA; Masuda A; Nowak JA; Nosho K; Kostic AD; Giannakis M; Watanabe H; Bullman S; Milner DA; Harris CC; Giovannucci E; Garraway LA; Freeman GJ; Dranoff G; Chan AT; Garrett WS; Huttenhower C; Fuchs CS; Ogino S
JAMA Oncol; 2015 Aug; 1(5):653-61. PubMed ID: 26181352
[TBL] [Abstract][Full Text] [Related]
9. Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer.
Sinicrope FA; Okamoto K; Kasi PM; Kawakami H
Clin Gastroenterol Hepatol; 2016 May; 14(5):651-8. PubMed ID: 26872400
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.
Dou R; Nishihara R; Cao Y; Hamada T; Mima K; Masuda A; Masugi Y; Shi Y; Gu M; Li W; da Silva A; Nosho K; Zhang X; Meyerhardt JA; Giovannucci EL; Chan AT; Fuchs CS; Qian ZR; Ogino S
Cancer Immunol Res; 2016 Nov; 4(11):927-935. PubMed ID: 27737877
[TBL] [Abstract][Full Text] [Related]
11. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.
Ogino S; Nowak JA; Hamada T; Phipps AI; Peters U; Milner DA; Giovannucci EL; Nishihara R; Giannakis M; Garrett WS; Song M
Gut; 2018 Jun; 67(6):1168-1180. PubMed ID: 29437869
[TBL] [Abstract][Full Text] [Related]
13. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival.
Mima K; Nowak JA; Qian ZR; Cao Y; Song M; Masugi Y; Shi Y; da Silva A; Gu M; Li W; Hamada T; Zhang X; Wu K; Meyerhardt JA; Baba H; Giovannucci EL; Chan AT; Fuchs CS; Ogino S; Nishihara R
Oncotarget; 2016 Aug; 7(34):55098-55109. PubMed ID: 27391152
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
[TBL] [Abstract][Full Text] [Related]
16. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
17. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
18. Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway.
Bae JM; Kim JH; Kang GH
Arch Pathol Lab Med; 2016 May; 140(5):406-12. PubMed ID: 27128298
[TBL] [Abstract][Full Text] [Related]
19. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.
Shen L; Toyota M; Kondo Y; Lin E; Zhang L; Guo Y; Hernandez NS; Chen X; Ahmed S; Konishi K; Hamilton SR; Issa JP
Proc Natl Acad Sci U S A; 2007 Nov; 104(47):18654-9. PubMed ID: 18003927
[TBL] [Abstract][Full Text] [Related]
20. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
Ogino S; Fuchs CS; Giovannucci E
Expert Rev Mol Diagn; 2012 Jul; 12(6):621-8. PubMed ID: 22845482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
